S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:TECH

Bio-Techne - TECH Stock Forecast, Price & News

$79.16
-1.69 (-2.09%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$77.66
$80.08
50-Day Range
$78.68
$327.07
52-Week Range
$68.00
$113.81
Volume
1.25 million shs
Average Volume
1.11 million shs
Market Capitalization
$12.43 billion
P/E Ratio
49.17
Dividend Yield
0.40%
Price Target
$104.45

Bio-Techne MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
32.0% Upside
$104.45 Price Target
Short Interest
Healthy
1.45% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.41
Upright™ Environmental Score
News Sentiment
0.27mentions of Bio-Techne in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$65,608 Sold Last Quarter
Proj. Earnings Growth
21.43%
From $1.82 to $2.21 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.28 out of 5 stars

Medical Sector

9th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

2nd out of 168 stocks

TECH stock logo

About Bio-Techne (NASDAQ:TECH) Stock

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. T

Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Stock News Headlines

“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Bio-Techne (TECH) Scheduled to Post Earnings on Thursday
Brokerages Set Bio-Techne Co. (NASDAQ:TECH) PT at $107.86
StockNews.com Lowers Bio-Techne (NASDAQ:TECH) to Hold
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Our 7 Top Biotech Stock Picks for 2023
Should You Invest in Bio-Techne Corporation (TECH)?
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Company Calendar

Last Earnings
11/01/2021
Ex-Dividend for 11/28 Dividend
11/10/2022
Dividend Payable
11/28/2022
Today
2/05/2023
Ex-Dividend for 2/27 Dividend
2/10/2023
Dividend Payable
2/27/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
3,000
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$104.45
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$89.00
Forecasted Upside/Downside
+32.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$272.05 million
Pretax Margin
28.39%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$2.47 per share
Book Value
$11.64 per share

Miscellaneous

Free Float
149,985,000
Market Cap
$12.43 billion
Optionable
Optionable
Beta
1.21

Social Links


Key Executives

  • Charles R. KummethCharles R. Kummeth
    President, Chief Executive Officer & Director
  • James T. HippelJames T. Hippel
    Chief Financial Officer
  • Brenda Swierenga Furlow
    Secretary & Chief Compliance Officer
  • Brenda S. Everson
    Chief Human Resources Officer & Senior VP
  • Robert M. Gavin
    Vice President-Corporate Development













TECH Stock - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TECH shares.
View TECH analyst ratings
or view top-rated stocks.

What is Bio-Techne's stock price forecast for 2023?

9 analysts have issued 12 month target prices for Bio-Techne's shares. Their TECH share price forecasts range from $89.00 to $120.00. On average, they predict the company's stock price to reach $104.45 in the next year. This suggests a possible upside of 32.0% from the stock's current price.
View analysts price targets for TECH
or view top-rated stocks among Wall Street analysts.

How have TECH shares performed in 2023?

Bio-Techne's stock was trading at $82.88 at the start of the year. Since then, TECH shares have decreased by 4.5% and is now trading at $79.16.
View the best growth stocks for 2023 here
.

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our TECH earnings forecast
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) issued its earnings results on Monday, November, 1st. The biotechnology company reported $0.46 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.03. The biotechnology company earned $257.72 million during the quarter, compared to analysts' expectations of $254.37 million. Bio-Techne had a trailing twelve-month return on equity of 15.87% and a net margin of 23.38%. During the same period in the previous year, the company posted $0.29 EPS.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne announced a quarterly dividend on Thursday, February 2nd. Investors of record on Monday, February 13th will be given a dividend of $0.08 per share on Monday, February 27th. This represents a $0.32 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Friday, February 10th. This is a positive change from the stock's previous quarterly dividend of $0.02.
Read our dividend analysis for TECH
.

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.40%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 19.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 14.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

When did Bio-Techne's stock split?

Bio-Techne shares split on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly created shares were payable to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (1.06%), Sumitomo Mitsui Trust Holdings Inc. (0.65%), Riverbridge Partners LLC (0.53%), New York State Common Retirement Fund (0.42%), Stephens Investment Management Group LLC (0.41%) and Artemis Investment Management LLP (0.30%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends
.

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $79.16.

How much money does Bio-Techne make?

Bio-Techne (NASDAQ:TECH) has a market capitalization of $12.43 billion and generates $1.12 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $1.61 on an earnings per share basis.

How many employees does Bio-Techne have?

The company employs 3,000 workers across the globe.

Does Bio-Techne have any subsidiaries?
The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.

This page (NASDAQ:TECH) was last updated on 2/5/2023 by MarketBeat.com Staff